Xact Kapitalforvaltning AB acquired a new stake in shares of Mirati Therapeutics Inc (NASDAQ:MRTX) in the first quarter, HoldingsChannel.com reports. The firm acquired 3,200 shares of the biotechnology company’s stock, valued at approximately $235,000.

A number of other large investors have also recently added to or reduced their stakes in MRTX. Janus Henderson Group PLC increased its stake in Mirati Therapeutics by 88.6% during the 1st quarter. Janus Henderson Group PLC now owns 2,034,744 shares of the biotechnology company’s stock valued at $149,147,000 after purchasing an additional 956,022 shares in the last quarter. BlackRock Inc. increased its stake in Mirati Therapeutics by 30.0% during the 4th quarter. BlackRock Inc. now owns 2,052,949 shares of the biotechnology company’s stock valued at $87,086,000 after purchasing an additional 474,097 shares in the last quarter. TimesSquare Capital Management LLC bought a new stake in shares of Mirati Therapeutics in the first quarter worth approximately $17,687,000. Jennison Associates LLC grew its stake in shares of Mirati Therapeutics by 21.8% in the fourth quarter. Jennison Associates LLC now owns 1,216,464 shares of the biotechnology company’s stock worth $51,602,000 after acquiring an additional 217,960 shares during the period. Finally, Perceptive Advisors LLC bought a new stake in shares of Mirati Therapeutics in the fourth quarter worth approximately $5,250,000.

MRTX opened at $94.26 on Friday. Mirati Therapeutics Inc has a 12-month low of $28.50 and a 12-month high of $102.59.

Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.20). The company had revenue of $1.24 million for the quarter. On average, equities research analysts expect that Mirati Therapeutics Inc will post -5 EPS for the current year.

MRTX has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Mirati Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, March 7th. Credit Suisse Group initiated coverage on shares of Mirati Therapeutics in a research note on Monday, March 25th. They issued an “outperform” rating and a $85.00 price target for the company. Cantor Fitzgerald initiated coverage on shares of Mirati Therapeutics in a research note on Monday, March 4th. They issued a “neutral” rating and a $66.00 price target for the company. BidaskClub lowered shares of Mirati Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 16th. Finally, Oppenheimer set a $81.00 price target on shares of Mirati Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $90.97.

In related news, Director Michael G. Grey sold 5,760 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $65.30, for a total value of $376,128.00. Following the transaction, the director now owns 7,100 shares of the company’s stock, valued at $463,630. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Venbio Select Advisor Llc sold 23,781 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $72.80, for a total transaction of $1,731,256.80. The disclosure for this sale can be found here. In the last three months, insiders sold 165,041 shares of company stock worth $12,464,235. 4.86% of the stock is currently owned by insiders.

WARNING: “Xact Kapitalforvaltning AB Acquires Shares of 3,200 Mirati Therapeutics Inc (NASDAQ:MRTX)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2019/06/16/xact-kapitalforvaltning-ab-acquires-shares-of-3200-mirati-therapeutics-inc-nasdaqmrtx.html.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

Further Reading: Cash Flow

Want to see what other hedge funds are holding MRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirati Therapeutics Inc (NASDAQ:MRTX).

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.